Program Partner: PharmSource, A GlobalData Company
Audiovisual Sponsor: West Pharmaceutical Services, Inc.
Beverage Break Sponsor: AMRI
Networking Reception Sponsorship: Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
In planning business strategies, pharmaceutical companies, contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs), and suppliers need to know how the global pharmaceutical market is performing, its strengths and weaknesses, and the trends and issues that will drive drug development and commercialization. Gain need-to-know information from industry experts that will provide:
Global Pharmaceutical Industry Outlook
Get the answers to these all-important questions:
Graham Lewis, Vice President, Global Pharma Strategy, QuintilesIMS
The Autoimmune Drug Market: The Opportunities and Challenges
Gain an in-depth market view of the autoimmune drug market, including leading pipeline contenders and commercial products and the positioning of key companies in this segment.
Christina Vasiliou, Senior Immunology & Inflammation Analyst, Datamonitor Healthcare
Executive Forum: A Conversation with John LaMattina, PhD, Former Senior Vice President, Pfizer Inc., and Former President, Pfizer Global Research and Development
Moderator: Kenneth I. Kaitin, PhD, Professor of Medicine and Director of the Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Tufts University
How are macro trends, such as R&D productivity, product mix, an evolving healthcare market, and drug pricing impacting drug development and commercialization now and in the future? What can the industry learn from its past to help deal with the challenges of today and what emerging issues may be on the horizon?
Gain the perspective of a pharmaceutical industry executive with more than 30 years of experience for a thought-provoking dialogue. As Senior Vice President, Pfizer Inc. and President, Pfizer Global Research and Development, Dr. LaMattina oversaw the drug discovery and development efforts of more than 12,000 employees in the United States, Europe, and Asia. Now a Senior Partner at PureTech Health, he is the author of several books, Drug Truths: Dispelling the Myths About Pharma R&D and Devalued and Distrusted–Can the Pharmaceutical Industry Restore Its Broken Image, and is a contributor to Forbes, where he writes on R&D and trends in the pharmaceutical industry.
Attendees should pre-register and pre-pay for DCAT Week programs and events before March 15, 2017 (5pm ET). Confirmations and receipts will be emailed to registrants when payment is received.
Member Badges: On or about Thursday, March 16, 2017, DCAT members will receive an email with an e-ticket attachment confirming all of their pre-registrations for DCAT Week. Attendees should print the e-ticket (or store it on their phone) and bring it with them to DCAT Week. The QR code on the ticket can be used to quickly print a member badge or to scan attendees into all of the programs and events they have pre-registered for throughout the week. A separate badge system will be used for non-member registrants.
Badge Pickup Locations during DCAT Week:
Walk-ins are welcome if space permits. All walk-ins must pay with a credit card or check. Walk-ins cannot be invoiced.
Speaker bios have been requested from presenters and will be posted here as they are received.
Dr. Kenneth I. Kaitin is Professor of Medicine and Director of the Tufts Center for the Study of Drug Development at Tufts University School of Medicine. Dr. Kaitin also holds appointments as Advisory Professor at Shanghai Medical College of Fudan University in Shanghai, China; Visiting Executive at the Tuck School of Business at Dartmouth College; and faculty of the European Center for Pharmaceutical Medicine at the University of Basel. An internationally recognized expert on drug development science and policy, Dr. Kaitin writes and speaks regularly on factors that contribute to the slow pace and high cost of pharmaceutical R&D and efforts to improve the development process. He has provided public testimony before the U.S. Congress on pharmaceutical development, regulation, and policy issues, and he currently serves as an expert consultant to the U.S. Department of Defense on bioterror countermeasures initiatives. Dr. Kaitin is frequently quoted in the business and trade press on global R&D trends and new models of innovation. A former President of the Drug Information Association, Dr. Kaitin is currently Editor-in-Chief of Expert Review of Clinical Pharmacology. He is on the editorial boards of a number of peer-review journals, and he serves on the boards of directors and scientific advisory boards of several public, private, and not-for-profit life sciences companies and organizations. In 2011, Dr. Kaitin received the Dr. Louis M. Sherwood Award, granted by the Academy of Pharmaceutical Physicians and Investigators. Dr. Kaitin received a B.S. from Cornell University and an M.S. and Ph.D. in pharmacology from the University of Rochester.
Dr. John L. LaMattina is the former Senior Vice President, Pfizer Inc. and President, Pfizer Global Research and Development. In this role, Dr. LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. He retired from this position in December, 2007.
Dr. LaMattina spent 30 years at Pfizer Inc. having joined as a medicinal chemist in 1977. Over the years, he held positions of increasing responsibility for Pfizer Central Research, including Vice President of US Discovery Operations in 1993, Senior Vice President of Worldwide Discovery Operations in 1998 and Senior Vice President of Worldwide Development in 1999.
Dr. LaMattina graduated cum laude from Boston College in 1971 with a B.S. in Chemistry. He attended the University of New Hampshire receiving a Ph.D. in Organic Chemistry in 1975. He then moved on to Princeton University as a National Institutes of Health Postdoctoral Fellow in the laboratory of Professor E. C. Taylor.
During his tenure as head of global R&D, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis, and AIDS. Dr. LaMattina is the author of numerous scientific publications and holds a number of U.S. patents. In addition, he is the author of “Drug Truths: Dispelling the Myths About Pharma R&D” and Devalued and Distrusted – Can the Pharmaceutical Industry Restore Its Broken Image? He is also a contributor to Forbes.com.
Dr. LaMattina has received a number of awards including the 1998 Boston College Alumni Award of Excellence in Science, an Honorary Doctor of Science degree from the University of New Hampshire in 2007, and the 2010 American Chemical Society Earle Barnes Award for Leadership in Chemical Research Management.
Dr. LaMattina is a Senior Partner and a member of the Board of Directors of PureTech Health. He serves on the Board of Directors of Ligand Pharmaceuticals, Zafgen, Gelesis, and Vedanta. Dr. LaMattina also serves as a Trustee Associate on the Board of Trustees of Boston College.
Graham Lewis is vice president, global pharma strategy at IMS Health. An economist by profession, Graham had, before entering the pharmaceutical industry, widespread experience of international market research, product management and business development at major industrial companies such as Philips and Cadbury Schweppes. Over the past 20 years, he has increasingly focused on strategic issues within the pharmaceutical industry, with particular emphasis on geographical growth opportunities, mergers and acquisitions, portfolio planning, forecasting and optimal launch planning and execution. He has spoken at conferences in Western Europe, North America, Latin America and the Far East, including China, and is widely sought after for his strategic insights. In May 2002, Graham was awarded the first Lifetime Achievement Award bestowed by the Pharmaceutical Business Intelligence and Research Group in recognition of his “outstanding lifetime contributions to the Pharmaceutical Industry and Market Research Profession”.
Christina Vasiliou is a Senior Analyst in the Immunology and Inflammation team at Datamonitor Healthcare, where she conducts extensive primary and secondary market research focusing on physician perspectives on marketed and emerging therapies in autoimmune indications. Ms. Vasiliou has produced analysis, financial forecasts, and opinion pieces for several indications, including rheumatoid arthritis, axial spondyloarthritis, psoriasis, atopic dermatitis, asthma, and chronic obstructive pulmonary disease. Prior to joining Datamonitor Healthcare, Ms. Vasiliou interned at PriceSpective, a value strategy consulting firm. Ms. Vasiliou holds an MPhil in Bioscience Enterprise from the University of Cambridge and a BSc in Biochemistry from Imperial College London.
Following the presentations, attendees are invited to a Networking Reception in the Empire Room 1 in the InterContinental from 4:30 to 6:00 pm.
InterContinental Barclay (Grand Ballroom)
111 East 48th Street
New York, New York 10017
Map & Directions
To cancel your program registration and receive a refund, you must call the DCAT office by March 15, 2017 (5pm ET) at +1-800-640-3228.
Refunds with receptions may be subject to a processing fee due to hotel guarantees.
The DCAT organization regrets that no refunds can be given after March 15, 2017 (5pm ET).
Registration payments made by credit card will be refunded within two to three business days from the date of cancellation.
Registration payments made by check will be refunded within 20 days of the program date.
Education program topics for DCAT Week are selected and developed by members of DCAT's Education Committee and other volunteer task forces of the organization. Speakers are selected based on their expertise and/or experience related to these topics, their ability to impart important information and concepts, and their willingness to do so without promoting specific business interests. By advance meetings with speakers, reviewing materials and slide presentations, DCAT volunteers make every effort to ensure that each program is a relevant, value-added experience for our members.
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.